Feed / JAZZ

Jazz Pharmaceuticals plc

JAZZ

Healthcare · 260.20 +2.3% today

Isolated · not yet confirmedMarket checked 25 Aug, 15:55 GMT-4

Jodie situation report

Jazz Pharmaceuticals plc's current read is isolated; its market group is not confirming.

The latest filing evidence is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 12 directly disclosed connections are confirming.

What changed
  • Revenue increased 15.5% versus the comparable filing period.
Company+2.3% todayVolume comparison unavailable
Market group0 of 2 activeBiotechnology · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • R&D costs increased as clinical studies and outside services for zanidatamab rose, with Jazz expecting further R&D growth.
  • Zepzelca sales growth is tied to increased volume and adoption in first-line maintenance ES-SCLC, partly offset by lower second-line use.

Invalidation: The isolated read changes if JAZZ's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind JAZZ

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AMRXAmneal Pharmaceuticals, Inc.customerAug 6, 2025

Specifically, a wholly owned subsidiary of Hikma launched its AG version of sodium oxybate in January 2023 and Amneal launched its AG version of sodium oxybate in July 2023.

ALKSAlkermes plcpartnerFeb 24, 2026

In addition, Alkermes acquired Avadel in February 2026, which may strengthen both companies and 23 Table of Contents we may experience increased competition from the combined company.

Depended on by

ALKSAlkermes plcpartnerMay 5, 2026

Pursuant to the settlement and license agreement entered into between Jazz Pharmaceuticals entities and Avadel entities in October 2025 (the “Avadel Settlement Agreement”), from October 1, 2025, Jazz receives a royalty of 3.85% (subject to certain adjustments…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

JAZZ is currently a Leader in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.